Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| REX | CLUSTER | neutral | 4/10 | Two REX insiders sold a total of ~$718K in stock within a 7-day window. The $614K sale by Executive COB Stuart Rose at $ | Jun 10, 2026 |
| GLAXF | 6-K | neutral | 1/10 | GSK filed a Form 6-K reporting a routine transaction by Maya Martinez-Davis, President US, who acquired 9.4289 notional | Jun 10, 2026 |
| OPTH | 6-K | bullish | 5/10 | Optimi Health Corp. announced its first export of naturally derived psilocybin (biomass and 5mg capsules) to the UK to s | Jun 10, 2026 |
| PLSE | 8-K | bullish | 6/10 | Pulse Biosciences announced it will redeem the remaining 200% Warrants (exercise price $11.00) from its July 2024 rights | Jun 10, 2026 |
| MEOBF | 6-K | bullish | 6/10 | Mesoblast provided an ASX CEO Connect presentation on June 2, 2026, highlighting the successful U.S. launch of Ryoncil, | Jun 10, 2026 |
| ZSQR | S-1 | bearish | 7/10 | Z Squared Inc. filed an S-1 registration statement to register 41,584,562 shares of common stock (80.85% of outstanding) | Jun 10, 2026 |
| RFL | 8-K | neutral | 5/10 | Rafael Holdings announced completion of the last patient's final 96-week visit in the pivotal Phase 3 TransportNPC study | Jun 10, 2026 |
| LSTA | PRESS-RELEASE | bullish | 7/10 | Lisata Therapeutics announced that Kuva Acquisition Corp. has commenced a tender offer to acquire all outstanding shares | Jun 10, 2026 |
| IXHL | PRESS-RELEASE | neutral | 3/10 | Incannex Healthcare received A$6.0 million (and expects ~A$5.1 million more) in non-dilutive R&D tax incentive proceeds | Jun 10, 2026 |
| CRVO | 8-K | bearish | 7/10 | CervoMed Inc. (CRVO) entered into a securities purchase agreement to sell $10.55 million in units at $3.14/unit, compris | Jun 10, 2026 |
| CGEM | PRESS-RELEASE | neutral | 4/10 | Cullinan Therapeutics released clinical data on two T cell engager programs (CLN-978 and velinotamig) for autoimmune dis | Jun 10, 2026 |
| RFL | PRESS-RELEASE | bullish | 7/10 | Rafael Holdings announced the last patient completed the final 96-week visit in its pivotal Phase 3 TransportNPC study f | Jun 10, 2026 |
| IXHL | 8-K | bullish | 5/10 | Incannex Healthcare announced receipt of A$6.0 million (approximately US$4M) in R&D Tax Incentive refund from the Austra | Jun 10, 2026 |
| CLYM | EFFECT | neutral | 4/10 | The SEC declared effective Climb Bio's S-3 registration statement (File No. 333-296346) on June 9, 2026. This shelf regi | Jun 10, 2026 |
| WHWK | EFFECT | bearish | 6/10 | The SEC declared effective Whitehawk Therapeutics' S-3 registration statement (File No. 333-296353) on June 9, 2026, cov | Jun 10, 2026 |
| INM | 8-K | neutral | 4/10 | InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, closing a delisting notice re | Jun 10, 2026 |
| STTK | PRESS-RELEASE | bearish | 6/10 | Shattuck Labs priced a public offering of 10,879,376 common shares at $4.00/share and pre-funded warrants for 7,870,624 | Jun 10, 2026 |
| TNGX | PRESS-RELEASE | bearish | 6/10 | Tango Therapeutics priced a $600M underwritten offering of 18.2M common shares and pre-funded warrants at $30/share, wit | Jun 9, 2026 |
| VRXA | 3 | neutral | 2/10 | Warren Hosseinion filed a Form 3 initial statement of beneficial ownership with the SEC, reporting 700,000 ordinary shar | Jun 9, 2026 |
| MIRM | CLUSTER | neutral | 3/10 | Three Mirum insiders, including the CEO and CFO, sold a total of $854K in open-market sales over a one-week window. The | Jun 9, 2026 |
| ABEO | CLUSTER | bearish | 5/10 | A cluster of insider sales at ABEO Therapeutics: CEO, CFO, Chief Commercial Officer, and Chief Legal Officer collectivel | Jun 9, 2026 |
| STLN | CLUSTER | neutral | 2/10 | A mixed insider cluster at Oncology Institute (TOI) shows a $126K open-market sale by the CMO and a $57K open-market pur | Jun 9, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three top insiders at United Therapeutics, the CEO, CFO, and General Counsel, executed a cluster of open-market sales to | Jun 9, 2026 |
| AXSM | 144 | neutral | 4/10 | CEO Herriot Tabuteau files Form 144 to sell 49,670 shares of Axsome Therapeutics (~$12.2M) under a 10b5-1 plan dated 3/1 | Jun 9, 2026 |
| VREOF | 8-K | neutral | 3/10 | Vireo Growth Inc. dismissed Davidson & Company LLP as independent auditor and appointed BDO USA, P.C. effective June 5, | Jun 9, 2026 |
| LBRX | 144 | neutral | 3/10 | Zachary Prensky, a former officer of LB Pharmaceuticals, filed a Form 144 notice of intent to sell 16,500 shares of comm | Jun 9, 2026 |
| NBIX | CLUSTER | neutral | 3/10 | A cluster of insider selling at Neurocrine Biosciences over the past week totals $4.53M in open-market sales by four off | Jun 9, 2026 |
| NBIX | CLUSTER | neutral | 2/10 | Four insiders at Neurocrine Biosciences sold a total of $4.53M in stock over a one-week window, including the Chief Scie | Jun 9, 2026 |
| TNXP | CLUSTER | bullish | 4/10 | CEO Seth Lederman and Director Richard Stillwell each purchased $59K and $58K worth of TNXP shares in open-market transa | Jun 9, 2026 |
| AXSM | 8-K | neutral | 2/10 | Axsome Therapeutics adopted a formal Executive Severance and Change in Control Plan effective June 5, 2026, covering the | Jun 9, 2026 |